Article Type
Changed
Thu, 06/20/2019 - 13:10
Display Headline
BEST PRACTICES: An Oral Treatment for Moderate to Severe Plaque Psoriasis

A Best Practices Supplement to Dermatology News. This supplement was sponsored by Celgene Corporation.

 

Faculty/Faculty Disclosures

Alan Menter, MD
Baylor University Medical Center
Dallas, TX

Dr Menter is on the advisory board for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Eli Lilly, Genentech Inc., Janssen Biotech, Inc., LEO Pharma and Pfizer; is a consultant for AbbVie, Allergan, Amgen, Convoy Therapeutics, Inc., Eli Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Vitae, Wyeth and XenoPort; is an investigator for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix and Wyeth; is a speaker for AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma and Wyeth; has received grant funds from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho and Syntrix; and has received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy Therapeutics, Inc., Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Vitae, Wyeth and XenoPort.

Copyright © by Frontline Medical Communications Inc.

Publications
Sections

A Best Practices Supplement to Dermatology News. This supplement was sponsored by Celgene Corporation.

 

Faculty/Faculty Disclosures

Alan Menter, MD
Baylor University Medical Center
Dallas, TX

Dr Menter is on the advisory board for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Eli Lilly, Genentech Inc., Janssen Biotech, Inc., LEO Pharma and Pfizer; is a consultant for AbbVie, Allergan, Amgen, Convoy Therapeutics, Inc., Eli Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Vitae, Wyeth and XenoPort; is an investigator for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix and Wyeth; is a speaker for AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma and Wyeth; has received grant funds from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho and Syntrix; and has received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy Therapeutics, Inc., Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Vitae, Wyeth and XenoPort.

Copyright © by Frontline Medical Communications Inc.

A Best Practices Supplement to Dermatology News. This supplement was sponsored by Celgene Corporation.

 

Faculty/Faculty Disclosures

Alan Menter, MD
Baylor University Medical Center
Dallas, TX

Dr Menter is on the advisory board for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Eli Lilly, Genentech Inc., Janssen Biotech, Inc., LEO Pharma and Pfizer; is a consultant for AbbVie, Allergan, Amgen, Convoy Therapeutics, Inc., Eli Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Vitae, Wyeth and XenoPort; is an investigator for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix and Wyeth; is a speaker for AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma and Wyeth; has received grant funds from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho and Syntrix; and has received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy Therapeutics, Inc., Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Vitae, Wyeth and XenoPort.

Copyright © by Frontline Medical Communications Inc.

Publications
Publications
Article Type
Display Headline
BEST PRACTICES: An Oral Treatment for Moderate to Severe Plaque Psoriasis
Display Headline
BEST PRACTICES: An Oral Treatment for Moderate to Severe Plaque Psoriasis
Sections
Disallow All Ads
Alternative CME
Use ProPublica